LDS/Medical Tests/Carnitine, Total, Serum/Plasma

Carnitine, Total, Serum/Plasma

Carnitine or β-hydroxy-γ-trimethylammonium butyrate is synthesized in the liver and kidney from lysine and methionine. It can also be obtained from the diet, primarily from meat products. Carnitine plays a very important role in the transportation of long-chain fatty acyl-CoA molecules from the cytosol into mitochondria where it is oxidized to generate energy. Therefore, carnitine is required for energy production from fat. Deficiency of carnitine is associated with impaired energy production and causes symptoms mostly in the fasting state. Evaluation of carnitine in serum and urine provide valuable information in regard to primary and secondary disorders of the carnitine cycle.

Primary carnitine deficiency, also known as carnitine update defect (CUD) is an autosomal recessive disorder, characterized by a defect in the carnitine/organic cation transporter novel 2 (OCTN2). In this disorder, fatty acyl CoA cannot be transported into mitochondria, resulting in impaired fatty acid oxidation. Due to the lack of carnitine transporter in the plasma membrane, intracellular carnitine content is significantly decreased while urinary excretion accelerates. Therefore, significant amounts (50 – 90%) of carnitine is lost in the urine. The incidence of CUD is approximately 1:40,000 newborns in the US population. Patients can present with hepatic encephalopathy or cardiomyopathy. Laboratory studies may show fasting hypoglycemia with minimal or no ketonuria, hyperammonemia and hepatic dysfunction. Secondary deficiency of carnitine may occur as a result of organic acidemias and disorders in fatty acid oxidation in which carnitine is trapped as fatty acyl CoA in cells resulting in its toxic accumulation and excretion into urine and bile as acylcarnitine. Rarely carnitine deficiency may occur in severe liver disease, malnutrition, total parenteral nutrition, chronic renal disease and patients on hemodialysis.

  • Aid in the diagnosis of primary and secondary carnitine deficiency
  • Useful in assessment of disorder in carnitine cycle and fatty acid oxidation
  • Useful in differential diagnosis of organic acidemias and fatty acid oxidation disorders
  • Useful in monitoring carnitine status

Increased in:

  • Myoglobinuria
  • Carnitine supplementation
  • After meat consumption

Decreased in:

  • Primary carnitine deficiency (carnitine update defect)
  • Carnitine palmitoyl transferase 1 deficiency
  • Carnitine palmitoyl transferase 2 deficiency
  • Carnitine-acylcarnitine translocase deficiency
  • Severe liver disease,
  • Malnutrition,
  • Total parenteral nutrition,
  • Chronic kidney disease
  • Hemodialysis
Serum Age Group Reference Range
1 day 23 – 68 μmol/L
2–7 days 17 – 41 μmol/L
8–31 days 19 – 59 μmol/L
1 month – 1 year 38 – 68 μmol/L
1 year – 6 years 35 – 84 μmol/L
7 – 10 years 28 – 83 μmol/L
11 – 18 years 34 – 77 μmol/L
>18 years 34 – 78 μmol/L
Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS), Liquid chromatography-tandem mass spectrometry (LC/MS-MS).

Serum (SST), plasma (EDTA)

Stability

  • Ambient: 3 hours
  • Refrigerated: 12 hours
  • Frozen: 1 month (avoid repeated freeze/thaw cycle)
Free carnitine, plasma acylcarnitine profile, DNA testing for disorder in fatty acid oxidation.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Eur J Pediatr. 1988;147(4):356-60. [PMID: 3396591]
  • Clin Chem. 2000;46(5):727-9. [PMID: 10794762]
  • Orphanet J Rare Dis. 2012;7:68. [PMID: 22989098]
  • Am J Med Genet C Semin Med Genet. 2006;142C(2):77-85. [PMID: 16602102]
  • Molecules. 2019 Sep 6;24(18). pii: E3251. [PMID: 31500110]
  • Pasquali M and Longo N. Newborn Screening and Inborn Errors of Metabolism. In Textbook of Clinical Chemistry and
  • Molecular Diagnostics. 6th ed. 2018. Page 1698 – 1730